Thiazolidinediones, dyslipidaemia and insulin resistance syndrome

Insulin resistance is known to unite several metabolic abnormalities. The associated dyslipidaemia appears to play a central role in this atherogenic syndrome. Thiazolidinediones, which are recently introduced insulin sensitizing agents, have been shown to be effective not only in reducing elevated...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in lipidology Vol. 11; no. 4; p. 397
Main Authors Sunayama, S, Watanabe, Y, Daida, H, Yamaguchi, H
Format Journal Article
LanguageEnglish
Published England 01.08.2000
Subjects
Chromans - therapeutic use
Clinical Trials as Topic
Glucose - metabolism
Humans
Hyperlipidemias - drug therapy
Hypoglycemic Agents - therapeutic use
Insulin Resistance
Phenotype
Thiazoles - adverse effects
Thiazoles - therapeutic use
Thiazolidinediones
Online AccessGet more information

Cover

More Information
Summary:Insulin resistance is known to unite several metabolic abnormalities. The associated dyslipidaemia appears to play a central role in this atherogenic syndrome. Thiazolidinediones, which are recently introduced insulin sensitizing agents, have been shown to be effective not only in reducing elevated glucose levels, but also in improving the other metabolic abnormalities that are associated with insulin resistance. The present review focuses on these potential effects of thiazolidinediones.
ISSN:0957-9672
DOI:10.1097/00041433-200008000-00009